LGND Ligand Pharmaceuticals Inc

Price (delayed)

$89.24

Market cap

$1.5B

P/E Ratio

62.85

Dividend/share

N/A

EPS

$1.42

Enterprise value

$1.68B

Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenx Inc., the company went public in 1992.

Highlights
The debt has contracted by 47% YoY and by 42% from the previous quarter
LGND's P/E is 45% below its 5-year quarterly average of 112.6 but 21% above its last 4 quarters average of 50.9
Ligand Pharmaceuticals's quick ratio has decreased by 44% QoQ but it has increased by 40% YoY
Ligand Pharmaceuticals's EPS has shrunk by 59% QoQ and by 41% YoY
Ligand Pharmaceuticals's net income has plunged by 59% from the previous quarter and by 40% YoY

Key stats

What are the main financial stats of LGND
Market
Shares outstanding
16.86M
Market cap
$1.5B
Enterprise value
$1.68B
Valuations
Price to earnings (P/E)
62.85
Price to book (P/B)
1.9
Price to sales (P/S)
5.61
EV/EBIT
46.83
EV/EBITDA
19.26
EV/Sales
6.29
Earnings
Revenue
$267.68M
EBIT
$35.98M
EBITDA
$87.49M
Free cash flow
$106.91M
Per share
EPS
$1.42
Free cash flow per share
$6.35
Book value per share
$47.07
Revenue per share
$15.91
TBVPS
$22.24
Balance sheet
Total assets
$1.11B
Total liabilities
$311.99M
Debt
$195.2M
Equity
$793.19M
Working capital
$233.49M
Liquidity
Debt to equity
0.25
Current ratio
6.48
Quick ratio
5.77
Net debt/EBITDA
2.06
Margins
EBITDA margin
32.7%
Gross margin
78.1%
Net margin
8.8%
Operating margin
24.2%
Efficiency
Return on assets
1.9%
Return on equity
2.9%
Return on invested capital
5%
Return on capital employed
3.4%
Return on sales
13.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LGND stock price

How has the Ligand Pharmaceuticals stock price performed over time
Intraday
1.63%
1 week
14.96%
1 month
9.42%
1 year
-33.97%
YTD
-42.22%
QTD
-20.67%

Financial performance

How have Ligand Pharmaceuticals's revenue and profit performed over time
Revenue
$267.68M
Gross profit
$208.95M
Operating income
$64.87M
Net income
$23.65M
Gross margin
78.1%
Net margin
8.8%
The company's operating income has surged by 142% YoY but it fell by 18% QoQ
Ligand Pharmaceuticals's operating margin has surged by 89% YoY but it has decreased by 15% QoQ
Ligand Pharmaceuticals's net income has plunged by 59% from the previous quarter and by 40% YoY
The net margin has plunged by 57% from the previous quarter and by 53% YoY

Growth

What is Ligand Pharmaceuticals's growth rate over time

Valuation

What is Ligand Pharmaceuticals stock price valuation
P/E
62.85
P/B
1.9
P/S
5.61
EV/EBIT
46.83
EV/EBITDA
19.26
EV/Sales
6.29
Ligand Pharmaceuticals's EPS has shrunk by 59% QoQ and by 41% YoY
LGND's P/E is 45% below its 5-year quarterly average of 112.6 but 21% above its last 4 quarters average of 50.9
LGND's P/B is 54% lower than its 5-year quarterly average of 4.1 and 33% lower than its last 4 quarters average of 2.8
The equity has grown by 6% year-on-year but it has declined by 3.4% since the previous quarter
The price to sales (P/S) is 61% lower than the 5-year quarterly average of 14.1 and 34% lower than the last 4 quarters average of 8.4
The revenue has grown by 28% year-on-year but it has declined by 3.4% since the previous quarter

Efficiency

How efficient is Ligand Pharmaceuticals business performance
The company's return on equity has shrunk by 60% QoQ and by 47% YoY
The ROA has shrunk by 58% QoQ and by 39% YoY
Ligand Pharmaceuticals's return on sales has decreased by 45% YoY and by 44% QoQ
Ligand Pharmaceuticals's ROIC has decreased by 43% from the previous quarter and by 7% YoY

Dividends

What is LGND's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LGND.

Financial health

How did Ligand Pharmaceuticals financials performed over time
Ligand Pharmaceuticals's quick ratio has decreased by 44% QoQ but it has increased by 40% YoY
Ligand Pharmaceuticals's total liabilities has decreased by 43% YoY and by 35% QoQ
The debt is 75% less than the equity
The debt to equity has contracted by 49% YoY and by 39% from the previous quarter
The debt has contracted by 47% YoY and by 42% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.